Neumora Therapeutics (NMRA) Competitors $0.78 +0.00 (+0.62%) Closing price 05/2/2025 04:00 PM EasternExtended Trading$0.78 0.00 (-0.15%) As of 05/2/2025 07:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock NMRA vs. GHRS, MNMD, SAGE, UPB, DNA, ABVX, RGNX, PGEN, CGEM, and SIGAShould you be buying Neumora Therapeutics stock or one of its competitors? The main competitors of Neumora Therapeutics include GH Research (GHRS), Mind Medicine (MindMed) (MNMD), Sage Therapeutics (SAGE), Upstream Bio (UPB), Ginkgo Bioworks (DNA), ABIVAX Société Anonyme (ABVX), REGENXBIO (RGNX), Precigen (PGEN), Cullinan Therapeutics (CGEM), and SIGA Technologies (SIGA). These companies are all part of the "pharmaceutical products" industry. Neumora Therapeutics vs. GH Research Mind Medicine (MindMed) Sage Therapeutics Upstream Bio Ginkgo Bioworks ABIVAX Société Anonyme REGENXBIO Precigen Cullinan Therapeutics SIGA Technologies Neumora Therapeutics (NASDAQ:NMRA) and GH Research (NASDAQ:GHRS) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their community ranking, risk, analyst recommendations, media sentiment, earnings, valuation, institutional ownership, dividends and profitability. Does the media favor NMRA or GHRS? In the previous week, GH Research had 3 more articles in the media than Neumora Therapeutics. MarketBeat recorded 5 mentions for GH Research and 2 mentions for Neumora Therapeutics. GH Research's average media sentiment score of 0.60 beat Neumora Therapeutics' score of 0.59 indicating that GH Research is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Neumora Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive GH Research 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is NMRA or GHRS more profitable? GH Research's return on equity of -20.29% beat Neumora Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Neumora TherapeuticsN/A -73.63% -68.97% GH Research N/A -20.29%-19.49% Which has more risk & volatility, NMRA or GHRS? Neumora Therapeutics has a beta of 2.89, suggesting that its stock price is 189% more volatile than the S&P 500. Comparatively, GH Research has a beta of 0.84, suggesting that its stock price is 16% less volatile than the S&P 500. Do insiders & institutionals believe in NMRA or GHRS? 47.7% of Neumora Therapeutics shares are held by institutional investors. Comparatively, 56.9% of GH Research shares are held by institutional investors. 26.4% of Neumora Therapeutics shares are held by company insiders. Comparatively, 41.6% of GH Research shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Which has better earnings & valuation, NMRA or GHRS? GH Research is trading at a lower price-to-earnings ratio than Neumora Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNeumora TherapeuticsN/AN/A-$235.93M-$1.53-0.51GH ResearchN/AN/A-$35.59M-$0.75-15.19 Does the MarketBeat Community prefer NMRA or GHRS? GH Research received 1 more outperform votes than Neumora Therapeutics when rated by MarketBeat users. Likewise, 76.92% of users gave GH Research an outperform vote while only 76.32% of users gave Neumora Therapeutics an outperform vote. CompanyUnderperformOutperformNeumora TherapeuticsOutperform Votes2976.32% Underperform Votes923.68% GH ResearchOutperform Votes3076.92% Underperform Votes923.08% Do analysts recommend NMRA or GHRS? Neumora Therapeutics presently has a consensus target price of $9.29, indicating a potential upside of 1,096.30%. GH Research has a consensus target price of $30.86, indicating a potential upside of 170.91%. Given Neumora Therapeutics' higher possible upside, research analysts plainly believe Neumora Therapeutics is more favorable than GH Research.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Neumora Therapeutics 1 Sell rating(s) 5 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.22GH Research 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummaryGH Research beats Neumora Therapeutics on 12 of the 15 factors compared between the two stocks. Get Neumora Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for NMRA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NMRA vs. The Competition Export to ExcelMetricNeumora TherapeuticsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$125.55M$2.97B$5.55B$8.03BDividend YieldN/A1.87%5.09%4.23%P/E Ratio-0.4230.5222.7518.87Price / SalesN/A493.12405.65106.84Price / CashN/A168.6838.1834.62Price / Book0.253.216.794.34Net Income-$235.93M-$72.35M$3.22B$248.06M7 Day Performance2.47%13.45%3.36%3.17%1 Month Performance-8.57%12.30%6.92%8.27%1 Year Performance-91.61%-23.52%16.15%5.03% Neumora Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NMRANeumora Therapeutics3.194 of 5 stars$0.78+0.6%$9.29+1,096.3%-91.6%$125.55MN/A-0.42108GHRSGH Research1.8085 of 5 stars$9.40-1.4%$30.86+228.3%+1.8%$489.06MN/A-11.9010News CoverageMNMDMind Medicine (MindMed)2.4339 of 5 stars$6.36+2.1%$25.11+294.8%-27.2%$479.34MN/A-2.8140Upcoming EarningsNews CoveragePositive NewsSAGESage Therapeutics3.9849 of 5 stars$7.77-0.3%$8.81+13.4%-44.3%$477.71M$41.24M-1.18690Earnings ReportAnalyst UpgradeAnalyst RevisionNews CoverageUPBUpstream BioN/A$8.78+4.6%$56.50+543.5%N/A$471.39M$2.37M0.0038News CoveragePositive NewsDNAGinkgo Bioworks0.8095 of 5 stars$8.02+2.3%$4.58-43.0%N/A$465.43M$227.04M-0.61640Upcoming EarningsNews CoverageGap UpABVXABIVAX Société Anonyme2.4555 of 5 stars$7.26+6.1%$38.00+423.4%-51.8%$460.42MN/A0.0061Analyst ForecastNews CoverageGap UpRGNXREGENXBIO4.4837 of 5 stars$9.13-0.2%$31.63+246.4%-37.5%$457.57M$83.33M-1.82370Upcoming EarningsNews CoveragePositive NewsPGENPrecigen3.687 of 5 stars$1.55+3.3%$7.00+351.6%+12.1%$455.77M$3.93M-2.82190News CoveragePositive NewsCGEMCullinan Therapeutics2.6821 of 5 stars$7.76-4.7%$34.80+348.5%-68.1%$454.06MN/A-2.7330Analyst RevisionSIGASIGA Technologies2.0554 of 5 stars$6.35-2.3%N/A-40.4%$453.65M$138.72M5.2940Upcoming EarningsEx-DividendOptions VolumeNews CoveragePositive News Related Companies and Tools Related Companies GH Research Competitors Mind Medicine (MindMed) Competitors Sage Therapeutics Competitors Upstream Bio Competitors Ginkgo Bioworks Competitors ABIVAX Société Anonyme Competitors REGENXBIO Competitors Precigen Competitors Cullinan Therapeutics Competitors SIGA Technologies Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:NMRA) was last updated on 5/3/2025 by MarketBeat.com Staff From Our PartnersThink NVDA’s run was epic? You ain’t seen nothin’ yetAsk most investors and they’ll probably tell you Nvidia is the undisputed AI stock of the decade. In 2023, ...Timothy Sykes | SponsoredElon’s Terrifying Warning Forces Trump To Take ActionElon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of col...American Hartford Gold | SponsoredTrump’s Bitcoin Reserve is No Accident…Bryce Paul believes this is the #1 coin to buy right now The catalyst behind this surge is a massive new b...Crypto 101 Media | SponsoredElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | SponsoredWhat President Trump’s Executive Order 14154 means for your moneyNearly $3 trillion disappeared from the stock market on Thursday morning. According to Whitney Tilson - a f...Stansberry Research | SponsoredHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredMost traders are panicking. We’re cashing inMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Neumora Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Neumora Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy NMRA Stock Free NMRA Stock Alerts